KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EPS (Weighted Average and Diluted) (2018 - 2025)

Amneal Pharmaceuticals (AMRX) has 8 years of EPS (Weighted Average and Diluted) data on record, last reported at $0.11 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 210.0% year-over-year to $0.11; the TTM value through Dec 2025 reached $0.22, up 157.89%, while the annual FY2025 figure was $0.22, 157.89% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.11 in Q4 2025 per AMRX's latest filing, up from $0.06 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.11 in Q4 2025 and bottomed at -$0.8 in Q2 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.07, with a median of $0.0 recorded in 2022.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 400.0% in 2023, down 1800.0% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.04 in 2021, then grew by 25.0% to -$0.03 in 2022, then plummeted by 1800.0% to -$0.57 in 2023, then soared by 82.46% to -$0.1 in 2024, then soared by 210.0% to $0.11 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $0.11 in Q4 2025, $0.06 in Q3 2025, and $0.07 in Q2 2025.